Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..
2021.
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Dutta E, DeJesus MA, Ruecker N, Zaveri A, Koh E-I, Sassetti CM, Schnappinger D, Ioerger TR.
2021.
An improved statistical method to identify chemical-genetic interactions by exploiting concentration-dependence.. PLoS One. 16(10):e0257911.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Harnagel A, Quezada LLopez, Park SWoong, Baranowski C, Kieser K, Jiang X, Roberts J, Vaubourgeix J, Yang A, Nelson B et al..
2021.
Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.. Mol Microbiol. 115(2):272-289.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..
2021.
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..
2021.
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..
2021.
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..
2021.
Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..
2021.
Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..
2021.
Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Barbet G, Nair-Gupta P, Schotsaert M, Yeung ST, Moretti J, Seyffer F, Metreveli G, Gardner T, Choi A, Tortorella D et al..
2021.
TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.. Nat Immunol. 22(4):497-509.